Contrasting Coloplast A/S (OTCMKTS:CLPBY) & Sanara MedTech (NASDAQ:SMTI)

Coloplast A/S (OTCMKTS:CLPBYGet Rating) and Sanara MedTech (NASDAQ:SMTIGet Rating) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, risk, dividends, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares Coloplast A/S and Sanara MedTech’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Coloplast A/S $2.76 billion 11.59 $585.21 million $0.30 49.40
Sanara MedTech $24.14 million 8.58 -$7.92 million ($1.08) -24.55

Coloplast A/S has higher revenue and earnings than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Coloplast A/S, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

0.1% of Coloplast A/S shares are owned by institutional investors. Comparatively, 4.8% of Sanara MedTech shares are owned by institutional investors. 59.2% of Sanara MedTech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.


This table compares Coloplast A/S and Sanara MedTech’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Coloplast A/S 21.62% 69.30% 33.77%
Sanara MedTech -32.81% -23.70% -20.83%

Volatility & Risk

Coloplast A/S has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500. Comparatively, Sanara MedTech has a beta of 2.28, suggesting that its share price is 128% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Coloplast A/S and Sanara MedTech, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Coloplast A/S 1 5 2 0 2.13
Sanara MedTech 0 0 1 0 3.00

Sanara MedTech has a consensus price target of $45.00, indicating a potential upside of 69.75%. Given Sanara MedTech’s stronger consensus rating and higher probable upside, analysts plainly believe Sanara MedTech is more favorable than Coloplast A/S.


Coloplast A/S beats Sanara MedTech on 9 of the 14 factors compared between the two stocks.

About Coloplast A/S (Get Rating)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates in three segments: Chronic Care, Interventional Urology, and Wound & Skin Care. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include bathing and cleansing products, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.

About Sanara MedTech (Get Rating)

Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako¯s Antimicrobial Skin and Wound Irrigation Solution. The company also provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a single layer sheet of amnion tissue. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with's FREE daily email newsletter.